OncoMatch/Clinical Trials/NCT06067841
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Is NCT06067841 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BMS-986460 for metastatic castration-resistant prostate cancer.
Treatment: BMS-986460 — The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen deprivation therapy
progressed on androgen deprivation therapy (ADT)
Must have received: secondary hormonal therapy — castration-resistant prostate cancer
at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Lab requirements
Cardiac function
must not have impaired cardiac function or clinically significant cardiac disease
Participant must not have impaired cardiac function or clinically significant cardiac disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Center · Palo Alto, California
- Florida Cancer Specialists Sarasota Drug Development Unit · Sarasota, Florida
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- Duke Cancer Institute · Durham, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify